Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 and Anlotinib in metastatic gastric cancer
NCT05029102Phase 2Recruiting
- Sponsor
- Zhejiang University
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trifluridine + tipiracil, anlotinib in gastric cancer (GC), sponsored by Zhejiang University. Started Sep 2021; status: recruiting.
02
Drugs
trifluridine + tipiracilanlotinib
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05029102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029102.